# $VOLT Social Sentiment & Intelligence — 2026-09-30 21:40 UTC

> **Asset:** $VOLT  
> **Momentum Status:** Low signal  
> **Timestamp:** 2026-09-30 21:40 UTC (2026-09-30T21:40:00Z)  
> **Canonical URL:** https://cryptitalk.com/2026-09-30-21-40/crypto/VOLT  
> **Overview Brief:** https://cryptitalk.com/2026-09-30-21-40/crypto.md  

---

## 10-Minute Social Metrics
- **Posts Analyzed:** 1
- **Total Impressions:** 127
- **Likes:** 5
- **Retweets:** 0
- **Comments:** 3

---


## Momentum & Sentiment Analysis
Total Engagement - Comments: 3, Retweets: 0, Likes: 5, Impressions: 127


---

## Cited Community Posts & Evidence


### Post #1 by @reddit
> **Author:** [@reddit](https://x.com/reddit)  
> **Metrics:** 5 likes · 0 retweets · 5 comments · 500 views  


> **Source Link:** [https://x.com/reddit/status/da6e821b0510a93b223a0a726b4d3686ed3d67702432008b818e95e434c4ca63](https://x.com/reddit/status/da6e821b0510a93b223a0a726b4d3686ed3d67702432008b818e95e434c4ca63)  


> 
> "Two new independent studies add even* more support to $ACRV

Two studies published this week add support for $ACRV’s drug ACR-368(prexasertib) Study 1: CAF-1 / chromatin assembly + prexasertib study:
https://www.biorxiv.org/content/10.64898/2026.09.27.754407v1 Study looked into CHK1 inhibition in cancer cells with defective chromatin assembly. Study shows that treatment with prexasertib let to significantly greater DNA damage, premature mitosis, and loss of viability. Study 2: DS5 / patient-derived tumor drug-screening study:"




---


## Contributing Accounts

- `@BillyMcgrath24` (https://x.com/BillyMcgrath24)